Biotech

All Articles

Amgen reports 1st phase 3 gain for $400M dermatitis medicine

.Amgen has actually shared (PDF) the initial phase 3 records on its own $400 million chronic eczema ...

Biogen, UCB report stage 3 lupus gain after failing earlier test

.Biogen and also UCB's depend advancing into phase 3 on the back of an unsuccessful research wants t...

Aptadir hopes new RNA preventions can turn around challenging cancers

.Italian biotech Aptadir Therapeutics has actually launched with the guarantee that its own pipe of ...

Wave surfs DMD success to regulators' doors, delivering stockpile

.Surge Lifestyle Sciences has actually met its own goal in a Duchenne muscular dystrophy (DMD) resea...

Sanofi plucks new CSO coming from in-stealth biotech

.After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, occupying the b...

Achilles droplets cell treatment system, supports for discharges after overlooking 'commercial practicality' objectives

.Achilles Therapies has actually torn up its technique. The English biotech is knocking off on its o...

Aligos declares period 2 MASH succeed, lowering liver excess fat up to 46%

.Aligos Therapeutics is actually trumpeting a midstage win in metabolic-dysfunction connected steato...

Basilea credit ratings $268M BARDA funding for antifungals, anti-biotics

.Basilea Pharmaceutica's job creating new antifungals has gotten a notable increase coming from the ...

Capricor offers Europe liberties to late-stage DMD therapy for $35M

.Having already scooped up the united state liberties to Capricor Therapeutics' late-stage Duchenne ...

FDA fragments adcomm for Applied's rare condition medicine

.After dismissing the selection date for Applied Therapies' metabolic disorder medication govorestat...